Free Trial
NASDAQ:ABEO

Abeona Therapeutics (ABEO) Stock Price, News & Analysis

Abeona Therapeutics logo
$5.54 +0.29 (+5.52%)
Closing price 10/8/2025 04:00 PM Eastern
Extended Trading
$5.60 +0.05 (+0.99%)
As of 10/8/2025 07:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Abeona Therapeutics Stock (NASDAQ:ABEO)

Advanced

Key Stats

Today's Range
$5.23
$5.73
50-Day Range
$5.25
$7.23
52-Week Range
$3.93
$7.54
Volume
1.12 million shs
Average Volume
1.08 million shs
Market Capitalization
$284.09 million
P/E Ratio
7.91
Dividend Yield
N/A
Price Target
$19.50
Consensus Rating
Moderate Buy

Company Overview

Abeona Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
87th Percentile Overall Score

ABEO MarketRank™: 

Abeona Therapeutics scored higher than 87% of companies evaluated by MarketBeat, and ranked 119th out of 942 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Abeona Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.

  • Upside Potential

    Abeona Therapeutics has a consensus price target of $19.50, representing about 252.0% upside from its current price of $5.54.

  • Amount of Analyst Coverage

    Abeona Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Abeona Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Abeona Therapeutics are expected to decrease in the coming year, from ($1.16) to ($1.23) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Abeona Therapeutics is 7.91, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 234.02.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Abeona Therapeutics is 7.91, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 85.47.

  • Price to Book Value per Share Ratio

    Abeona Therapeutics has a P/B Ratio of 5.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Abeona Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    19.14% of the float of Abeona Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Abeona Therapeutics has a short interest ratio ("days to cover") of 9.8.
  • Change versus previous month

    Short interest in Abeona Therapeutics has recently decreased by 3.32%, indicating that investor sentiment is improving.
  • Dividend Yield

    Abeona Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Abeona Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    19.14% of the float of Abeona Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Abeona Therapeutics has a short interest ratio ("days to cover") of 9.8.
  • Change versus previous month

    Short interest in Abeona Therapeutics has recently decreased by 3.32%, indicating that investor sentiment is improving.
  • News Sentiment

    Abeona Therapeutics has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Abeona Therapeutics this week, compared to 4 articles on an average week.
  • Search Interest

    10 people have searched for ABEO on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Abeona Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Abeona Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,221,990.00 in company stock.

  • Percentage Held by Insiders

    Only 6.90% of the stock of Abeona Therapeutics is held by insiders.

  • Percentage Held by Institutions

    80.56% of the stock of Abeona Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Abeona Therapeutics' insider trading history.
Receive ABEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Abeona Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ABEO Stock News Headlines

URGENT: The Market's 3 Red Flags Are Flashing
The warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gold price (signaling fear), and escalating geopolitical risk. A sharp correction might happen tomorrow, and most investors will be caught off guard. Your portfolio is currently exposed.tc pixel
Should You Invest in Abeona Therapeutics (ABEO)?
See More Headlines

ABEO Stock Analysis - Frequently Asked Questions

Abeona Therapeutics' stock was trading at $5.57 at the beginning of the year. Since then, ABEO stock has decreased by 0.5% and is now trading at $5.54.

Abeona Therapeutics Inc. (NASDAQ:ABEO) posted its earnings results on Thursday, August, 14th. The biopharmaceutical company reported $1.71 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $2.10. The biopharmaceutical company earned $0.40 million during the quarter, compared to analysts' expectations of $21.71 million.
Read the conference call transcript
.

Shares of Abeona Therapeutics reverse split on Tuesday, July 5th 2022.The 1-25 reverse split was announced on Tuesday, July 5th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 5th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Shares of ABEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Abeona Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), CymaBay Therapeutics (CBAY) and GE Aerospace (GE).

Company Calendar

Last Earnings
8/14/2025
Today
10/08/2025
Next Earnings (Estimated)
11/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ABEO
Previous Symbol
OTCMKTS:ACCP
CIK
318306
Employees
90
Year Founded
2013

Price Target and Rating

High Price Target
$20.00
Low Price Target
$18.00
Potential Upside/Downside
+252.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.70
Trailing P/E Ratio
7.91
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$63.73 million
Net Margins
N/A
Pretax Margin
18,188.50%
Return on Equity
89.05%
Return on Assets
45.64%

Debt

Debt-to-Equity Ratio
0.09
Current Ratio
6.73
Quick Ratio
6.65

Sales & Book Value

Annual Sales
$3.50 million
Price / Sales
81.17
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.01 per share
Price / Book
5.49

Miscellaneous

Outstanding Shares
51,280,000
Free Float
48,510,000
Market Cap
$284.09 million
Optionable
Optionable
Beta
1.42

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:ABEO) was last updated on 10/9/2025 by MarketBeat.com Staff
From Our Partners